恶性血液病降钙素基因高度甲基化的研究

Study on Hypermethylation of the Calcitonin Gene in Malignant Hematol ogical Disorders

目的 探讨降钙素 ( CT)基因高度甲基化在恶性血液病中的临床意义。方法 采用限制性内切酶 ( HPa )消化 DNA和聚合酶链反应技术检测 73例恶性血液病、6例正常人以及 2 4例非恶性血液病的 CT基因的甲基化程度。结果 12 / 14例 ( 85 .7% )急性淋巴细胞白血病、9/ 15例 ( 6 0 % )急性非淋巴细胞白血病、8/ 10例( 80 % )慢性粒细胞白血病、5 / 15例 ( 33.3% )淋巴瘤、2例 ( 2 / 5 )骨髓增生异常综合征、1例 ( 1/ 2 )恶性组织细胞病、1例 ( 1/ 3)慢性淋巴细胞白血病和 1例 ( 1/ 9)多发性骨髓瘤的病人出现 CT基因高度甲基化阳性。而 6例正常人和 2 4例非恶性血液病无一例阳性。结论 CT基因高度甲基化可作为恶性血液病恶性克隆增殖的分子基因标志 ,从而为恶性血液病的诊断。

Objective To investigate the clinical significanc e of hypermethyla tion of the calcitonin (CT) gene in malignant hematological disorders (MHD). Methods Polymerase chain reaction (PCR) in combination with digest ion of DNA with H paⅡwas used to examine the methylation patterns of the CT gene in 73 patients w ith MHD, 6 healthy people and 24 patients with nonmalignant hematological disord ers (NON MHD). Results Hypermethylation of the CT gene occurre d in 12 of 14 (85.7%) patients with acute lymphoblastic leukemia (ALL), 9 of 15 (60%) acute nonly mphocytic leukemia (ANLL), 8 of 10 (80%) chronic myelogenous leukemia (CML), 5 of 15 (33.3%) malignant lymphoma (ML), 2 of 5 patients with myelodysplastic synd rome(MDS), 1 of 2 malignant histiocytosis (MH), 1 of 3 chronic lymphocytic leuk emia (CLL) and 1 of 9 multiple myeloma (MM). However, it did not occur in normal controls and NON MHD. Conclusion Hypermethylation of CT gene may serve as an imp ortant molecular maker for tumorous cell clone and may be useful in diagnosing M HD, monitoring minimal residual disease and predicting prognosis.